Ultragenyx Reports Positive Long-Term Data for UX111 Gene Therapy, Bolstering BLA Resubmission

summarizeSummary

Ultragenyx reported strong long-term clinical data for its UX111 gene therapy for Sanfilippo syndrome type A, showing significant functional and biomarker improvements, which were included in its recently resubmitted BLA to the FDA.

check_boxKey Events

• Positive Long-Term Clinical Data for UX111

  New data from clinical studies evaluating UX111 gene therapy for Sanfilippo syndrome type A (MPS IIIA) demonstrated substantial and durable biomarker improvements and meaningful functional benefits compared to natural history.

• Significant Functional Improvements Observed

  Children under two years or with earlier-stage disease showed a +23.2 point treatment effect in Bayley-III cognitive raw scores. Improvements were also noted in receptive and expressive communication, and fine and gross motor skills.

• Functional Skill Retention in Later-Stage Children

  Patients with more advanced disease showed retention of functional abilities (communication, ambulation, self-feeding) that exceed typical decline patterns in untreated children.

• Favorable Safety Profile Confirmed

  UX111 was generally well-tolerated across all doses, with treatment-related adverse events being mostly mild or moderate and resolving spontaneously.

auto_awesomeAnalysis

Ultragenyx Pharmaceutical Inc. announced compelling long-term clinical data for its UX111 gene therapy, which targets Sanfilippo syndrome type A (MPS IIIA), a severe neurodegenerative disorder. The data demonstrates significant and durable improvements in biomarkers and functional abilities across various age groups and disease stages, compared to natural history. This positive outcome, coupled with a favorable safety profile, strengthens the company's Biologics License Application (BLA) for UX111, which was recently resubmitted to the FDA. The anticipated PDUFA date in the third quarter of 2026 marks a critical milestone for potential accelerated approval, offering hope for patients with this fatal condition.